SeromYx Systems
SeromYx is a specialist Contract Research Organization (CRO) founded in July 2019 to commercialize its Systems Serology platform. This platform combines 12 high-throughput assays with machine learning computational analysis to provide unprecedented insight into immune function, particularly Fc-mediated antibody effector functions. Developed by Dr. Galit Alter at the Ragon Institute with support from DARPA and the Bill and Melinda Gates Foundation, the platform measures how innate immune cells are recruited to clear pathogens, infected cells, or tumor cells, ultimately determining which functions drive efficacy. SeromYx's mission is to help pharmaceutical and biotechnology companies design better vaccines and immunotherapies by understanding features associated with protection. They operate on a fee-for-service model without entanglement of client intellectual property. The platform is applicable across various therapeutic areas, including therapeutic antibodies, vaccines, SARS-CoV2, autoimmunity, and oncology. SeromYx is GCLP accredited and expects to double in size to support the development of next-generation coronavirus vaccines and expand into new therapeutic areas.
SeromYx Systems
SeromYx is a specialist Contract Research Organization (CRO) founded in July 2019 to commercialize its Systems Serology platform. This platform combines 12 high-throughput assays with machine learning computational analysis to provide unprecedented insight into immune function, particularly Fc-mediated antibody effector functions. Developed by Dr. Galit Alter at the Ragon Institute with support from DARPA and the Bill and Melinda Gates Foundation, the platform measures how innate immune cells are recruited to clear pathogens, infected cells, or tumor cells, ultimately determining which functions drive efficacy. SeromYx's mission is to help pharmaceutical and biotechnology companies design better vaccines and immunotherapies by understanding features associated with protection. They operate on a fee-for-service model without entanglement of client intellectual property. The platform is applicable across various therapeutic areas, including therapeutic antibodies, vaccines, SARS-CoV2, autoimmunity, and oncology. SeromYx is GCLP accredited and expects to double in size to support the development of next-generation coronavirus vaccines and expand into new therapeutic areas.